-
1
-
-
0027179491
-
Present status and future prospects for HIV therapies
-
Johnston MI, Hoth DF. Present status and future prospects for HIV therapies. Science 1993;260:1286 -1291
-
(1993)
Science
, vol.260
-
-
Johnston, M.I.1
Hoth, D.F.2
-
2
-
-
0025221948
-
Human immunodeficiency virus protease: A target for AIDS therapy
-
Debouck C, Metcalf BW. Human immunodeficiency virus protease: a target for AIDS therapy. Drug Dev Res 1990;21:1-17
-
(1990)
Drug Dev Res
, vol.21
, pp. 1-17
-
-
Debouck, C.1
Metcalf, B.W.2
-
4
-
-
0025952925
-
HIV protease: A novel chemotherapeutic target for AIDS
-
Huff JR. HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem 1991;34:2305-2314
-
(1991)
J Med Chem
, vol.34
, pp. 2305-2314
-
-
Huff, J.R.1
-
5
-
-
0027218692
-
Structure-based inhibitors of HIV-1 protease
-
Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 1993;62:543-585
-
(1993)
Annu Rev Biochem
, vol.62
, pp. 543-585
-
-
Wlodawer, A.1
Erickson, J.W.2
-
6
-
-
0028248489
-
HIV protease as an inhibitor target for the treatment of AIDS
-
Darke PL, Huff JR. HIV protease as an inhibitor target for the treatment of AIDS. Adv Pharmacol 1994;25:399-454
-
(1994)
Adv Pharmacol
, vol.25
, pp. 399-454
-
-
Darke, P.L.1
Huff, J.R.2
-
7
-
-
0027969994
-
The design of a potent orally bioavailable HIV protease inhibitor
-
735, 524
-
Dorsey BD, Levin RB, McDaniel SL, et al. 735, 524: the design of a potent orally bioavailable HIV protease inhibitor. J Med Chem 1994; 37:344-351
-
(1994)
J Med Chem
, vol.37
, pp. 344-351
-
-
Dorsey, B.D.1
Levin, R.B.2
Mc Daniel, S.L.3
-
8
-
-
0028110476
-
Use of proteinase inhibitors in clinical practice
-
Pollard R. Use of proteinase inhibitors in clinical practice. Pharmacotherapy 1994; 14:21S-9S
-
(1994)
Pharmacotherapy
, vol.14
-
-
Pollard, R.1
-
9
-
-
0028968902
-
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
-
Kempf DJ, Marsh KV, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Nall Acad Sci USA 1995;92:2484-2488
-
(1995)
Proc Nall Acad Sci USA
, vol.92
, pp. 2484-2488
-
-
Kempf, D.J.1
Marsh, K.V.2
Denissen, J.F.3
-
10
-
-
84959793850
-
Evaluation of the antiviral activity of orally administered ABT-538, an inhibitor of HIV-1 protease [abstract 185]
-
(Washington, DC).Washington, DC: American Society for Microbiology
-
Markowitz M, Jalil L, Hurley A, et al. Evaluation of the antiviral activity of orally administered ABT-538, an inhibitor of HIV-1 protease [abstract 185]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections
, pp. 1995
-
-
Markowitz, M.1
Jalil, L.2
Hurley, A.3
-
11
-
-
0028874048
-
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
-
Ho DD, Neumann AU, Pcrclson AS, Wen C, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126
-
(1995)
Nature
, vol.373
, pp. 123-126
-
-
Ho, D.D.1
Neumann, A.U.2
Pcrclson, A.S.3
Wen, C.4
Leonard, J.M.5
Markowitz, M.6
-
12
-
-
84959833936
-
A randomized, double blind study of the oral HIV protease inhibitor, L-735, 524 vs. Zidovudine (ZDV) in p24 antigenemic, HIV-1 infected patients with <500 CD4 cells/mm3 [abstract 183]
-
Washington, DC: American Society for Microbiology
-
Mellors J, Steigbigcl R, Gulick R, et al. A randomized, double blind study of the oral HIV protease inhibitor, L-735, 524 vs. zidovudine (ZDV) in p24 antigenemic, HIV-1 infected patients with <500 CD4 cells/mm3 [abstract 183]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections (Washington, DC)
, pp. 1995
-
-
Mellors, J.1
Steigbigcl, R.2
Gulick, R.3
-
13
-
-
0028811974
-
Viral dynamics in human immunodeficiency virus type 1 infection
-
Wei X, Ghosh SK, Taylor ME, el al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122
-
(1995)
Nature
, vol.373
, pp. 117-122
-
-
Wei, X.1
Ghosh, S.K.2
Taylor, M.E.3
-
14
-
-
0028943992
-
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
-
Condra JH, Schleif WA, Blahy OM, el al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571
-
(1995)
Nature
, vol.374
, pp. 569-571
-
-
Condra, J.H.1
Schleif, W.A.2
Blahy, O.M.3
-
15
-
-
84959831010
-
In vitro antiviral and resistance studies of AGI343 an orally bioavailable inhibitor of HIV-1 protease [abstract 184]
-
(Washington, DC), Washington, DC: American Society for Microbiology
-
Patick AK, Mo H, Markowitz M, Ho D, Webber S. In vitro antiviral and resistance studies of AGI343 an orally bioavailable inhibitor of HIV-1 protease [abstract 184]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections
, pp. 1995
-
-
Patick, A.K.1
Mo, H.2
Markowitz, M.3
Ho, D.4
Webber, S.5
-
16
-
-
84959823789
-
Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor [abstract 186]
-
(Washington, DC), Washington, DC: American Society for Microbiology
-
Fischl MA, Richman DD, Flcxncr C, et al. Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor [abstract 186]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections
, pp. 1995
-
-
Fischl, M.A.1
Richman, D.D.2
Flcxncr, C.3
-
17
-
-
84959831327
-
Phase I study of A77003, an HIV protease inhibitor, in man [abstract WS-B26-6]
-
London: Wellcome Foundation
-
Danner SA, Reedijk M, Boucher CA. Phase I study of A77003, an HIV protease inhibitor, in man [abstract WS-B26-6]. In: Program and abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin). London: Wellcome Foundation, 1993
-
Program and Abstracts: IX International Conference on AIDS/IV STD World Congress (Berlin)
, pp. 1993
-
-
Danner, S.A.1
Reedijk, M.2
Boucher, C.A.3
-
18
-
-
0027401867
-
Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNi-174, in rats after intravenous and intraduodenal administrations
-
Kiriyama A, Mimoto T, Kiso Y, Takada K. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNi-174, in rats after intravenous and intraduodenal administrations. Biopharm Drug Dispos 1993; 14:199-207
-
(1993)
Biopharm Drug Dispos
, vol.14
, pp. 199-207
-
-
Kiriyama, A.1
Mimoto, T.2
Kiso, Y.3
Takada, K.4
-
19
-
-
0028231995
-
Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentration proteins
-
Kageyama SS, Anderson BD, Hoesterey BL, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentration proteins. Antimicrob Agents Chemother 1994;38:1107-1111
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 1107-1111
-
-
Kageyama, S.S.1
Erson, B.D.2
Hoesterey, B.L.3
-
20
-
-
0025955611
-
Ct al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease
-
Kcmpf DJ, Marsh KC, Paul DA, ct al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991; 35:2209-2214
-
(1991)
Antimicrob Agents Chemother
, vol.35
, pp. 2209-2214
-
-
Kcmpf, D.J.1
Marsh, K.C.2
Paul, D.A.3
-
21
-
-
0028951411
-
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum «¡-acid glycoprotein
-
Bilello JA, Bilello PA, Prichard M, Robins T, Drusano GL. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum «¡-acid glycoprotein. J Infect Dis 1995;171:546-551
-
(1995)
J Infect Dis
, vol.171
, pp. 546-551
-
-
Bilello, J.A.1
Bilello, P.A.2
Prichard, M.3
Robins, T.4
Drusano, G.L.5
-
22
-
-
0028846226
-
Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
-
Kim EE, Baker CT, Dwyer MD, et al. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995;117:1181-1182
-
(1995)
J am Chem Soc
, vol.117
, pp. 1181-1182
-
-
Kim, E.E.1
Baker, C.T.2
Dwyer, M.D.3
-
23
-
-
84959832404
-
An overview of the preclini-cal development of the HIV protease inhibitor VX-478 (141W94) [abstract LB5]
-
Washington, DC: American Society for Microbiology
-
Painter GR, St Clair MH, DeMiranda P, et al. An overview of the preclini-cal development of the HIV protease inhibitor VX-478 (141W94) [abstract LB5]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections (Washington, DC)
, pp. 1995
-
-
Painter, G.R.1
St Clair, M.H.2
Demiranda, P.3
-
24
-
-
0025799991
-
An improved colorimetric assay for cell proliferation and viability utilizing the tetra-zolium salt XTT
-
Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetra-zolium salt XTT. J Tmmunol Methods 1991;142:257-265
-
(1991)
J Tmmunol Methods
, vol.142
, pp. 257-265
-
-
Roehm, N.W.1
Rodgers, G.H.2
Hatfield, S.M.3
Glasebrook, A.L.4
-
25
-
-
0027310686
-
Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV)
-
Øie S, Jacobson MA, Abrams DI. Alpha 1-acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993;5:531-533
-
(1993)
J Acquir Immune Defic Syndr
, vol.5
, pp. 531-533
-
-
Øie, S.1
Jacobson, M.A.2
Abrams, D.I.3
-
26
-
-
84959844240
-
Drug binding and apparent volume of distribution
-
Tillement JP, Lindendlaub E, eds., Germany: Schattauer
-
Houin G. Drug binding and apparent volume of distribution. In: Tillement JP, Lindendlaub E, eds. Protein binding and drug transport. Stuggart, Germany: Schattauer, 1985:213-226
-
(1985)
Protein Binding and Drug Transport. Stuggart
, pp. 213-226
-
-
Houin, G.1
-
27
-
-
0027212863
-
El al. Effect of human serum on the in vitro anti-HIV activity of l-[(2-hydroxyethoxy)methyl]-6(phenylthio) thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding
-
Baba M, Yuasa S, Niwa T, el al. Effect of human serum on the in vitro anti-HIV activity of l-[(2-hydroxyethoxy)methyl]-6(phenylthio) thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem Phdrmacol 1993;45:2507-2512
-
(1993)
Biochem Phdrmacol
, vol.45
, pp. 2507-2512
-
-
Baba, M.1
Yuasa, S.2
Niwa, T.3
-
28
-
-
0019952227
-
Importance of protein binding for the interpretation of serum or plasma drug concentration
-
Greenblatt DJ, Sellers EM, Koch-Weser J. Importance of protein binding for the interpretation of serum or plasma drug concentration. J Clin Pharmacol 1982; 22:259-63
-
(1982)
J Clin Pharmacol
, vol.22
, pp. 259-263
-
-
Greenblatt, D.J.1
Sellers, E.M.2
Koch-Weser, J.3
-
29
-
-
0023690101
-
Drug binding to human alpha-1 -acid glycoprotein in health and disease
-
Kremer JMH, Wilting J, Janssen LHM. Drug binding to human alpha-1 -acid glycoprotein in health and disease. Phannacol Rev 1988;40:1-47
-
(1988)
Phannacol Rev
, vol.40
, pp. 1-47
-
-
Kremer, J.1
Wilting, J.2
Janssen, L.3
-
30
-
-
0021041788
-
In vivo binding of propranolol and progesterone to native and desialylated human orosomucoid
-
Wong AKL, Hsia JC. In vivo binding of propranolol and progesterone to native and desialylated human orosomucoid. Can J Biochem Cell Biol 1983;61:1114-1116
-
(1983)
Can J Biochem Cell Biol
, vol.61
, pp. 1114-1116
-
-
Wong, A.1
Hsia, J.C.2
-
31
-
-
84959809551
-
A human serum glycoprotein profoundly affects antiviral activity of the protcase inhibitor SC-52151 by decreasing its cellular uptake [abstract LB4]
-
Washington, DC: American Society for Microbiology
-
Sommadossi JP, Schinazi RE, McMillan A, Xie MY, Bryant M. A human serum glycoprotein profoundly affects antiviral activity of the protcase inhibitor SC-52151 by decreasing its cellular uptake [abstract LB4]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995
-
Program and Abstracts of the 2Nd National Conference on Human Retroviruses and Related Infections (Washington, DC)
, pp. 1995
-
-
Sommadossi, J.P.1
Schinazi, R.E.2
Mc Millan, A.3
Xie, M.Y.4
Bryant, M.5
|